Technical Analysis for TCON - TRACON Pharmaceuticals, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 1.91 | 1.06% | 0.02 |
Earnings due: May 8
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| NR7 | Range Contraction | 1.06% | |
| NR7-2 | Range Contraction | 1.06% | |
| Narrow Range Bar | Range Contraction | 1.06% | |
| Inside Day | Range Contraction | 1.06% | |
| Wide Bands | Range Expansion | 1.06% | |
| Oversold Stochastic | Weakness | 1.06% | |
| NR7 | Range Contraction | 3.24% | |
| Narrow Range Bar | Range Contraction | 3.24% | |
| Wide Bands | Range Expansion | 3.24% | |
| Oversold Stochastic | Weakness | 3.24% |
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | about 2 hours ago |
| Up 3% | about 2 hours ago |
| Up 2% | about 2 hours ago |
| Up 1% | about 3 hours ago |
| Possible NR7 | about 22 hours ago |
Get a Trading Assistant
- Earnings date: 05/08/2024
TRACON Pharmaceuticals, Inc. Description
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focused on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration, and fibrotic diseases. Its lead product candidate is TRC105, which is in Phase II clinical trials for oncology indications, including soft tissue sarcoma, renal cell carcinoma, glioblastoma, and hepatocellular carcinoma. The company is planning for clinical trials of TRC105, including a Phase II clinical trial in patients with breast cancer and hepatocellular carcinoma, a Phase I clinical trial in patients with colorectal cancer, and a Phase I clinical trial in patients with lung cancer, as well as conducting preclinical studies of TRC105 in AMD. In addition, the company product candidates comprise TRC205, an anti-endoglin antibody that is in preclinical stage for the treatment of fibrotic diseases; and TRC102, a small molecule, which is in clinical development for the treatment of lung cancer and glioblastoma. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Drugs Clinical Development Breast Cancer Clinical Trial Treatment Of Breast Cancer Colorectal Cancer Blastoma Macular Degeneration Glioblastoma Lung Cancer Sarcoma Carcinoma Targeted Therapy Hepatocellular Carcinoma Age Related Macular Degeneration Renal Cell Carcinoma Soft Tissue Sarcoma Fibrotic Disease Therapeutics For Cancer Transgene Sa
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 16.8 |
| 52 Week Low | 1.59 |
| Average Volume | 279,342 |
| 200-Day Moving Average | 4.42 |
| 50-Day Moving Average | 4.96 |
| 20-Day Moving Average | 3.93 |
| 10-Day Moving Average | 2.04 |
| Average True Range | 0.88 |
| RSI (14) | 28.06 |
| ADX | 27.19 |
| +DI | 24.91 |
| -DI | 31.65 |
| Chandelier Exit (Long, 3 ATRs) | 7.36 |
| Chandelier Exit (Short, 3 ATRs) | 4.23 |
| Upper Bollinger Bands | 8.81 |
| Lower Bollinger Band | -0.94 |
| Percent B (%b) | 0.29 |
| BandWidth | 247.77 |
| MACD Line | -1.21 |
| MACD Signal Line | -1.01 |
| MACD Histogram | -0.1924 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.05 | ||||
| Resistance 3 (R3) | 2.05 | 2.00 | 2.03 | ||
| Resistance 2 (R2) | 2.00 | 1.95 | 2.00 | 2.02 | |
| Resistance 1 (R1) | 1.94 | 1.93 | 1.97 | 1.94 | 2.01 |
| Pivot Point | 1.89 | 1.89 | 1.90 | 1.89 | 1.89 |
| Support 1 (S1) | 1.83 | 1.84 | 1.86 | 1.84 | 1.77 |
| Support 2 (S2) | 1.78 | 1.82 | 1.78 | 1.76 | |
| Support 3 (S3) | 1.72 | 1.78 | 1.75 | ||
| Support 4 (S4) | 1.73 |
